We evaluated responses to PD-1 blockade therapy in a cohort of 71 patients with MMR-d cancers from various anatomical sites treated in the Drug Rediscovery Protocol (DRUP)23 in relation to their B2M status (Fig. 1a, Extended Data Fig. 1a–c and Supplementary Table 1). The gene discussed is PDCD1; the disease is cancer.